The license includes a carve-out by BIG for use of the technology in its non-Hodgkin lymphoma (NHL) vaccine which is currently under development.
The license leaves Stellar free to commercialise the technology, exclusively, in all other fields.
Stellar CEO Frank Oakes said the technology developed through the collaboration with BIG represents a breakthrough in the production of characterised, immunogenically potent carrier proteins (ICPs), not only in terms of quality and purity, but also for cost management in the final drug product.
"The technology will be integrated into BIG’s NHL vaccine platform, and commercialised broadly by Stellar for other vaccines and related products," Oakes said.